

Yoon-Sim Yap

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/2560956/yoon-sim-yap-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

55
papers

1,056
citations

16
h-index

31
g-index

58
ext. papers

1,427
ext. citations

6.9
avg, IF

3.72
L-index

#	Paper	IF	Citations
55	Abstract GS2-01: Overall survival subgroup analysis by metastatic site from the phase 3 MONALEESA-2 study of first-line ribociclib + letrozole in postmenopausal patients with advanced HR+/HER2- breast cancer. <i>Cancer Research</i> , 2022 , 82, GS2-01-GS2-01	10.1	0
54	HER2 expression, copy number variation and survival outcomes in HER2-low non-metastatic breast cancer: an international multicentre cohort study and TCGA-METABRIC analysis.. <i>BMC Medicine</i> , 2022 , 20, 105	11.4	2
53	Fatty acid oxidation is a druggable gateway regulating cellular plasticity for driving metastasis in breast cancer. <i>Science Advances</i> , 2021 , 7, eabh2443	14.3	5
52	Regulatory and operational challenges in conducting Asian International Academic Trial for expanding the indications of cancer drugs. <i>Clinical and Translational Science</i> , 2021 , 14, 1015-1025	4.9	0
51	Tissue-specific cell-free DNA degradation quantifies circulating tumor DNA burden. <i>Nature Communications</i> , 2021 , 12, 2229	17.4	9
50	Individualized Molecular Profiling for Allocation to Clinical Trials Singapore Study-An Asian Tertiary Cancer Center Experience. <i>JCO Precision Oncology</i> , 2021 , 5,	3.6	1
49	Effects of housing value and medical subsidy on treatment and outcomes of breast cancer patients in Singapore: A retrospective cohort study. <i>The Lancet Regional Health - Western Pacific</i> , 2021 , 6, 100065 ⁵		3
48	Microfluidic studies of hydrostatic pressure-enhanced doxorubicin resistance in human breast cancer cells. <i>Lab on A Chip</i> , 2021 , 21, 746-754	7.2	3
47	A Phase I Study of LSZ102, an Oral Selective Estrogen Receptor Degradar, with or without Ribociclib or Alpelisib, in Patients with Estrogen Receptor-Positive Breast Cancer. <i>Clinical Cancer Research</i> , 2021 , 27, 5760-5770	12.9	6
46	Analysis of the pan-Asian subgroup of patients in the NALA Trial: a randomized phase III NALA Trial comparing neratinib+capecitabine (N+C) vs lapatinib+capecitabine (L+C) in patients with HER2+metastatic breast cancer (mBC) previously treated with two or more HER2-directed regimens. <i>Breast Cancer Research and Treatment</i> , 2021 , 189, 665-676	4.4	2
45	An Overview of the Treatment Efficacy and Side Effect Profile of Pharmacological Therapies in Asian Patients with Breast Cancer. <i>Targeted Oncology</i> , 2021 , 16, 701-741	5	0
44	Liquid biopsies for residual disease and recurrence.. <i>Med</i> , 2021 , 2, 1292-1313	31.7	1
43	Phase I Trial of Expanded, Activated Autologous NK-cell Infusions with Trastuzumab in Patients with HER2-positive Cancers. <i>Clinical Cancer Research</i> , 2020 , 26, 4494-4502	12.9	13
42	Impact of deviation from guideline recommended treatment on breast cancer survival in Asia. <i>Scientific Reports</i> , 2020 , 10, 1330	4.9	10
41	Integrative Analysis and Machine Learning based Characterization of Single Circulating Tumor Cells. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	16
40	Human epidermal growth factor receptor 2 positive rates in invasive lobular breast carcinoma: The Singapore experience. <i>World Journal of Clinical Oncology</i> , 2020 , 11, 283-293	2.5	0
39	Detection of genomic alterations in breast cancer with circulating tumour DNA sequencing. <i>Scientific Reports</i> , 2020 , 10, 16774	4.9	4

38	Impact of Cryotherapy on Sensory, Motor, and Autonomic Neuropathy in Breast Cancer Patients Receiving Paclitaxel: A Randomized, Controlled Trial. <i>Frontiers in Neurology</i> , 2020 , 11, 604688	4.1	3
37	Neratinib after trastuzumab-based adjuvant therapy in patients from Asia with early stage HER2-positive breast cancer. <i>Future Oncology</i> , 2019 , 15, 2489-2501	3.6	5
36	Detection and prognostic relevance of circulating tumour cells (CTCs) in Asian breast cancers using a label-free microfluidic platform. <i>PLoS ONE</i> , 2019 , 14, e0221305	3.7	7
35	Assessment of PARP4 as a candidate breast cancer susceptibility gene. <i>Breast Cancer Research and Treatment</i> , 2019 , 177, 145-153	4.4	6
34	Patterns of relapse after neoadjuvant chemotherapy in breast cancer: implications for surveillance in clinical practice. <i>Breast Cancer Research and Treatment</i> , 2019 , 177, 197-206	4.4	7
33	Insights Into Breast Cancer in the East vs the West: A Review. <i>JAMA Oncology</i> , 2019 , 5, 1489-1496	13.4	47
32	Contrasting Epidemiology and Clinicopathology of Female Breast Cancer in Asians vs the US Population. <i>Journal of the National Cancer Institute</i> , 2019 , 111, 1298-1306	9.7	47
31	Low-dose anti-inflammatory combinatorial therapy reduced cancer stem cell formation in patient-derived preclinical models for tumour relapse prevention. <i>British Journal of Cancer</i> , 2019 , 120, 407-423	8.7	21
30	Treating HR+/HER2- breast cancer in premenopausal Asian women: Asian Breast Cancer Cooperative Group 2019 Consensus and position on ovarian suppression. <i>Breast Cancer Research and Treatment</i> , 2019 , 177, 549-559	4.4	20
29	Validation of a Risk Score Incorporating Tumor Characteristics into the American Joint Committee on Cancer Anatomic Stage for Breast Cancer. <i>Journal of Breast Cancer</i> , 2019 , 22, 260-273	3	2
28	BioPATH: A Biomarker Study in Asian Patients with HER2+ Advanced Breast Cancer Treated with Lapatinib and Other Anti-HER2 Therapy. <i>Cancer Research and Treatment</i> , 2019 , 51, 1527-1539	5.2	2
27	Replication and Meta-analysis of the Association between BDNF Val66Met Polymorphism and Cognitive Impairment in Patients Receiving Chemotherapy. <i>Molecular Neurobiology</i> , 2019 , 56, 4741-4750	6.2	12
26	Breast cancer risk in neurofibromatosis type 1 is a function of the type of gene mutation: a new genotype-phenotype correlation. <i>Journal of Medical Genetics</i> , 2019 , 56, 209-219	5.8	19
25	Genotype-Phenotype Correlation in NF1: Evidence for a More Severe Phenotype Associated with Missense Mutations Affecting NF1 Codons 844-848. <i>American Journal of Human Genetics</i> , 2018 , 102, 69-87	11	93
24	Distinct and heterogeneous trajectories of self-perceived cognitive impairment among Asian breast cancer survivors. <i>Psycho-Oncology</i> , 2018 , 27, 1185-1192	3.9	25
23	Association of mitochondrial DNA content in peripheral blood with cancer-related fatigue and chemotherapy-related cognitive impairment in early-stage breast cancer patients: a prospective cohort study. <i>Breast Cancer Research and Treatment</i> , 2018 , 168, 713-721	4.4	10
22	Breast cancer in women with neurofibromatosis type 1 (NF1): a comprehensive case series with molecular insights into its aggressive phenotype. <i>Breast Cancer Research and Treatment</i> , 2018 , 171, 719-735	11	11
21	Elucidating therapeutic molecular targets in premenopausal Asian women with recurrent breast cancers. <i>Npj Breast Cancer</i> , 2018 , 4, 19	7.8	15

20	Evaluation of three polygenic risk score models for the prediction of breast cancer risk in Singapore Chinese. <i>Oncotarget</i> , 2018 , 9, 12796-12804	3.3	13
19	A preliminary study for the assessment of PD-L1 and PD-L2 on circulating tumor cells by microfluidic-based chipcytometry. <i>Future Science OA</i> , 2017 , 3, FSO244	2.7	15
18	Chromosome 1q21.3 amplification is a trackable biomarker and actionable target for breast cancer recurrence. <i>Nature Medicine</i> , 2017 , 23, 1319-1330	50.5	77
17	Predictors of Hand-Foot Syndrome and Pyridoxine for Prevention of Capecitabine-Induced Hand-Foot Syndrome: A Randomized Clinical Trial. <i>JAMA Oncology</i> , 2017 , 3, 1538-1545	13.4	42
16	Identification of Novel Breast Cancer Risk Loci. <i>Cancer Research</i> , 2017 , 77, 5428-5437	10.1	10
15	Inherited breast cancer predisposition in Asians: multigene panel testing outcomes from Singapore. <i>Npj Genomic Medicine</i> , 2016 , 1, 15003	6.2	31
14	Brain-derived neurotrophic factor genetic polymorphism (rs6265) is protective against chemotherapy-associated cognitive impairment in patients with early-stage breast cancer. <i>Neuro-Oncology</i> , 2016 , 18, 244-51	1	56
13	DNA methyltransferase 1 (DNMT1) polymorphism and chemotherapy-associated cognitive impairment in early-stage breast cancer patients (ESBC): A prospective, longitudinal study.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 10014-10014	2.2	1
12	Phase Ib/II trial of expanded and activated autologous natural killer (NK) cells with trastuzumab (Tras) in refractory HER2+ metastatic breast cancer (MBC).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3045-3045	3.3	32
11	Patient Management with Eribulin in Metastatic Breast Cancer: A Clinical Practice Guide. <i>Journal of Breast Cancer</i> , 2016 , 19, 8-17	3	10
10	Association of CYP2C19*2 and associated haplotypes with lower norendoxifen concentrations in tamoxifen-treated Asian breast cancer patients. <i>British Journal of Clinical Pharmacology</i> , 2016 , 81, 1142-52	3.8	16
9	Pharmacogenetics of UGT1A4, UGT2B7 and UGT2B15 and Their Influence on Tamoxifen Disposition in Asian Breast Cancer Patients. <i>Clinical Pharmacokinetics</i> , 2016 , 55, 1239-1250	6.2	20
8	Whole-exome sequencing of breast cancer, malignant peripheral nerve sheath tumor and neurofibroma from a patient with neurofibromatosis type 1. <i>Cancer Medicine</i> , 2015 , 4, 1871-8	4.8	25
7	Predictive Factors for BRCA1 and BRCA2 Genetic Testing in an Asian Clinic-Based Population. <i>PLoS ONE</i> , 2015 , 10, e0134408	3.7	14
6	Evaluation of brain-derived neurotrophic factor (BDNF) genetic polymorphism (rs6265) on chemotherapy-associated cognitive impairment in early-stage breast cancer (ESBC) patients.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 9616-9616	2.2	4
5	Predictors of hand-foot syndrome (HFS) in randomised double-blind, placebo-controlled trial of pyridoxine for prevention of capecitabine induced HFS.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 9596-9596	2.2	2
4	Evaluation of pro-inflammatory cytokines and anxiety symptoms in early-stage breast cancer (ESBC) patients: A prospective, longitudinal study.. <i>Journal of Clinical Oncology</i> , 2015 , 33, e20742-e20742	2.2	2
3	Minimal clinically important difference (MCID) for the functional assessment of cancer therapy: cognitive function (FACT-Cog) in breast cancer patients. <i>Journal of Clinical Epidemiology</i> , 2014 , 67, 811-20	5.7	65

- | | | | |
|---|--|-----|-----|
| 2 | Clinical validation of an ultra high-throughput spiral microfluidics for the detection and enrichment of viable circulating tumor cells. <i>PLoS ONE</i> , 2014 , 9, e99409 | 3-7 | 139 |
| 1 | The NF1 gene revisited - from bench to bedside. <i>Oncotarget</i> , 2014 , 5, 5873-92 | 3-3 | 91 |